Results 111 to 120 of about 28,421 (276)

Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination

Nature Communications, 2021
By conferring systemic protection and durable benefits, cancer immunotherapies are emerging as long-term solutions for cancer treatment. One such approach that is currently undergoing clinical testing is a therapeutic anti-cancer vaccine that uses two ...
D. Roy, K. Geoffroy, M. Marguerie, S. T. Khan, N. Martin, J. Kmiecik, D. Bobbala, A. Aitken, C. D. de Souza, K. Stephenson, B. Lichty, R. Auer, D. Stojdl, J. Bell, M. Bourgeois-Daigneault   +14 more
semanticscholar   +1 more source

Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1

Advanced Science, Volume 12, Issue 48, December 29, 2025.
This study identifies transmembrane protein adipocyte‐associated 1 (TPRA1) as a novel receptor for oncolytic virus M1 (OVM). TPRA1's ectodomain binds OVM particles, while its intracellular domain facilitates virus internalization, promoting efficient viral entry.
Linyi Hu, Guigen Zhang, Yuan Lin, Shiming Yi, Jingyu Yang, Xueying Lin, Deli Song, Zhiheng Liu, Jiayu Zhang, Ying Zeng, Shanyu Huang, Zhen Fan, Jifu Zhang, Ying Liu, Cheng Hu, Wenbo Zhu, Wei Yin, Jun Hu, Guangmei Yan, Jing Cai, Jiankai Liang   +20 more
wiley   +1 more source

HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy [PDF]

, 2014
Several clinical trials have shown that oncolytic herpes simplex virus type 1 (oHSV-1) can be safely administered to patients. However, virus replication in tumor tissue has generally not been monitored in these oHSV clinical trials, and the data suggest
Decklever, T D, Li, H, Nace, R A, Nakashima, H, Russell, S J   +4 more
core   +1 more source

Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy

Cancers, 2022
Simple Summary More than half of children with high-risk neuroblastoma will not survive despite aggressive treatment regimens. The discovery of suitable novel therapies that target high-risk disease remain limited.
Colin H. Quinn, Andee M. Beierle, S. Hutchins, Raoud Marayati, Laura V. Bownes, J. Stewart, Hooper R. Markert, Michael H. Erwin, Jamie M. Aye, K. Yoon, G. Friedman, C. Willey, J. Markert, E. Beierle   +13 more
semanticscholar   +1 more source

Mathematical Modeling and Optimal Control of Combined Virotherapy and Adoptive T Cell Therapy for Cancer Treatment

Mathematical Methods in the Applied Sciences, Volume 48, Issue 18, Page 16263-16289, December 2025.
ABSTRACT In this study, we investigate the synergistic roles of adoptive T cell therapy (ACT), specifically using tumor‐infiltrating lymphocytes (TILs) and oncolytic virus (OV) therapy in enhancing cancer treatment efficacy. While OVs can initiate tumor destruction, they often fail to achieve complete tumor eradication or generate a strong antitumor ...
Salaheldin Omer, Hermane Mambili‐Mamboundou, Rachid Ouifki   +2 more
wiley   +1 more source

Current landscape and perspective of oncolytic viruses and their combination therapies

Translational Oncology, 2022
Oncolytic virotherapy has become an important strategy in cancer immunotherapy. Oncolytic virus (OV) can reshape the tumor microenvironment (TME) through its replication-mediated oncolysis and transgene-produced anticancer effect, inducing an antitumor ...
Yinghan Su, Changqing Su, Lunxiu Qin
doaj   +1 more source

Oncolytic virotherapy against the tumor microenvironment and its potential in pancreatic cancer

Journal of Cancer Research and Therapeutics, 2022
Emerging evidence has revealed the critical role of the tumor microenvironment (TME) in tumor progression, angiogenesis, metastasis, and immunosuppression. Oncolytic viruses (OVs), a versatile therapeutic agent that targets both cancer cells and the TME,
Yalei Zhang, Ye Li, Kun Chen, L. Qian, Peng Wang   +4 more
semanticscholar   +1 more source

Figure S2 from Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models [PDF]

, 2023
Dipongkor Saha, Hiroaki Wakimoto, Cole W. Peters, Slawomir J. Antoszczyk, Samuel D. Rabkin, Robert L. Martuza   +5 more
openalex   +1 more source

Toward Translation of Cowpea Mosaic Virus Intratumoral Immunotherapy With a Scalable Production Process

Plant Biotechnology Journal, Volume 23, Issue 11, Page 5013-5031, November 2025.
ABSTRACT The plant virus cowpea mosaic virus (CPMV) is being developed as a drug candidate for intratumoral immunotherapy for solid tumours. Data from preclinical studies in mice and rats as well as clinical studies in canine cancer patients demonstrate potent efficacy and an excellent safety profile.
Patrick Opdensteinen, Jessica Fernanda Affonso de Oliveira, Seongwon Jung, Nicole F. Steinmetz   +3 more
wiley   +1 more source

Oncolytic Virotherapy: From Bench to Bedside

Frontiers in Cell and Developmental Biology, 2021
Oncolytic viruses are naturally occurring or genetically engineered viruses that can replicate preferentially in tumor cells and inhibit tumor growth. These viruses have been considered an effective anticancer strategy in recent years.
Ludi Yang, X. Gu, Jie Yu, S. Ge, Xianqun Fan   +4 more
semanticscholar   +1 more source